OBJECTIVE： To observe the efficacy and safety of paclitaxel combined with cisplatin and fluorouracil for gastric cancer with liver metastases via indwelling hepatic arterial catheter. METHODS： 56 gastric cancer patients with liver metastases were randomly divided into control group （28 cases） and observation group （28 cases）. Control group received Paclitaxel injection 135 mg/m2，d1+Cisplatin injection 75 mg/m2，d1+Fluorouracil injection 750 mg/m2，d1-5，pumping administrated via central venous. Observation group received Paclitaxel injection 135 mg/m2，d1+Cisplatin injection 75 mg/m2，d1+Fluorouracil injection 750 mg/m2， d1-5，administrated via indwelling hepatic arterial catheter. 3-4 weeks were a course， it lasted 8 courses at most. Magnesium isoglycyrrhizinate injection 200 mg/d was intravenously infused for liver protection in 2 groups during treatment. Clinical efficacy， serum carcinoembryonic antigen （CEA）， alanine aminotransferase （ALT）， aspartate aminotransferase （AST） levels before and after treatment， and the incidence of adverse reactions in 2 groups observed. RESULTS： Short-term clinical efficacy in observation group was significantly higher than control group， with statistical significance （P＜0.01）. Before treatment， there were no significant differences in CEA， ALT and AST levels （P＞0.05）. After treatment， CEA， ALT and AST levels in 2 groups were significantly higher than before， ALT and AST levels in observation group were significantly higher than control group， while CEA level in observation group was lower than control group， with statistical significances （P＜0.05）. The incidences of bone marrow suppression， nausea， vomiting and fever in observation group were significantly lower than control group， with statistical significances （P＜0.05）. CONCLUSIONS： Paclitaxel combined with cisplatin and fluorouracil has good efficacy for gastric cancer with liver metastases via indwelling hepatic arterial catheter， while it exists liver dysfunction.